News

As per the terms of the collaboration, Adcentrx will specify the targets against which AvantGen will screen for new antibodies by making use of its yeast display system.

The acceptance by the FDA is based on the positive data from a Phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

As part of the collaboration, the companies will use Nurosene’s core AI tools, NetraHealthAtlas, to speed up the drug discovery process. NetraHealthAtlas is designed to produce insights regarding

Lead founding investors Polaris Partners and Timothy A. Springer participated in the funding round, in addition to new investors Samsara BioCapital, Boxer Capital, GV, and management and founders.

As per the agreement, Healx intends to investigate the compound as part of a potential combination therapy for Fragile X syndrome and treatment for other indications. Fragile X

The drug attaches to a specific protein on the cancer cells’ surface and helps the immune system to detect and attack them. Approximately 100 women with advanced and

Enjaymo is intended to reduce the need for red blood cell transfusion caused due to hemolysis in CAD patients. The drug is a humanised monoclonal antibody that selectively

As part of the collaboration, Janssen will provide its antibodies and Mersana will apply its Dolasynthen platform and expertise for the discovery of the new ADC product candidates.

As part of the collaboration, both the companies will co-develop AVT23, an investigational compound, that is now in late development stage. The companies will develop the proposed biosimilar